Innovstone Therapeutics Ltd. has synthesized leucine-rich repeat kinase 2 (LRRK2; Dardarin) inhibitors reported to be useful for the treatment of Parkinson’s disease.
Moma Therapeutics Inc. has disclosed tricyclic derivatives acting as Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
The first patent from Palo Alto, Calif.-headquartered Updoc Inc. provides protection for their development of an artificially intelligent, voice-based method for prescribing, managing and administering at least one medication for management of type 2 diabetes to a patient.
Scientists at Mayo Foundation for Medical Education and Research (MFMER) and Sanford Burnham Prebys Medical Discovery Institute have described G-protein coupled bile acid receptor 1 (GPBAR1; TGR5; GPCR19; GPR131) antagonists reported to be useful for the treatment of cancer and polycystic liver.
Tenvie Therapeutics Inc. has divulged NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of glaucoma, spinal cord injury, multiple sclerosis, Niemann-Pick disease, Alzheimer’s disease, amyotrophic lateral sclerosis, stroke and diabetic neuropathy, among others.
City of Hope has disclosed proliferating cell nuclear antigen (PCNA) inhibitors acting as apoptosis inducers reported to be useful for the treatment of cancer.
The renal denervation patent wars are now in full swing, with subsidiaries of Medtronic plc and Recor Medical LLC, landing the first blow in this chapter of the med tech patent struggles.
Mainline Biosciences (Shanghai) Co. Ltd. has described peptide-drug conjugates consisting of peptide targeting somatostatin receptors covalently bound to cytotoxic agents through a linker reported to be useful for the treatment of cancer.
RSS
